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A New Stage in the History of Publishing Seminal
Experimental Pathology Research in the JournalWith this issue, The American Journal of Pathology car-
ries a new designation: Published by Elsevier, Inc. This
is the next in a long line of evolutionary changes for the
Journal, changes that have enabled it to remain dy-
namic, responsive to, and reflective of our authors,
readers, and Society members who comprise the re-
search pathology community.
A History of Change
Change is not new to the Journal or to its parent Soci-
ety. The Journal has a rich publication history stretch-
ing back more than 100 years.1 Its roots can be found
in The Journal of the Boston Medical Sciences, first pub-
lished in 1896 and later published by Harvard Univer-
sity Press as The Journal of Medical Research beginning
in 1901. The first issue bearing the name The American
Journal of Pathology appeared in January 1925, pub-
lished as the official journal of the American Associa-
tion of Pathologists and Bacteriologists (AAPB). In
1976, the AAPB merged with the American Society for
Experimental Pathology, a founding member of the
Federation of American Societies for Experimental Pa-
thology, to form the American Association of Patholo-
gists (AAP). This was then reincorporated in 1992 as
the current American Society for Investigative Pathol-
ogy (ASIP). That same year, Nelson Fausto began his
tenure as Editor-in-Chief of The American Journal of
Pathology, and the Journal itself began its life as a
self-published journal.
I have had the opportunity to be part of the leader-
ship of the Society since 1990. That was a banner year
for me. I published my first article2 in the Journal and
also attended my first ASIP Council meeting as Chair of
the Education Committee. At that time, the Journal was
published commercially by J. B. Lippincott Co. I was
part of the leadership that decided to move the Journal
to self-publication 19 years ago, and since then, as
Council member, ASIP President, and now Executive
Officer, I have witnessed and been proud to be an
active force in the Journal’s evolution and growth.
2Growth Through Change
As the Journal begins this next phase of its evolution, the
question naturally arises: Was self-publication an exper-
iment that failed? Hardly. Under the leadership of our
appointed Editors (Nelson Fausto, James Madara, Jay
McDonald, and now Michael Lisanti), in-house journal
staff, and Publications Committees and other Society
leadership, The American Journal of Pathology has expe-
rienced tremendous success in its tenure as a self-pub-
lished journal. We have developed incredibly rich and
deep expertise in the practices and policies surrounding
biomedical publishing, enjoyed financial stability, and
fortified the Journal’s position as the premier resource
and most-cited journal in research pathology.
Our goal in embarking on this relationship with Elsevier
is not because we are stepping back from our commit-
ment to the Journal but because we want to ensure the
continued focus by the Society on editorial quality, while
also allowing a broader framework for dissemination of
scientific discovery and introduction of technological en-
hancement. The decision to move to managed publica-
tion was not undertaken lightly. Scientific publishing is
undergoing tremendous pressures from factors such as
the Open Access movement, adoption of new publishing
and discoverability technologies, and increased global-
ization of content. This changing climate has put tradi-
tional revenue streams such as institutional subscriptions
at risk, while also demanding higher levels of diligence,
investment, and innovation. While The American Journal of
Pathology has had strong success as a self-published
nonprofit society journal, ASIP wants to ensure that the
Journal remains able to provide continued technological
innovation and financial stability, while still ensuring the
high editorial and production quality of published articles.
Understanding the Future
So what does this mean? Under managed publishing, the
Society still owns the Journal, maintains copyright, and
retains full editorial control, but production, promotion,
and other publishing support services are provided by
the contract publisher. The American Journal of Pathology
remains the official journal of the ASIP, and our commit-
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Journal’s role in fulfilling that commitment remains firm.
Our journal website will continue to make publicly avail-
able those articles that were published more than 12
months previously. Society members will continue to re-
ceive the Journal online as a member benefit, and the
surcharge for optional print issues will remain at its low
cost (and in fact, will be less costly for international mem-
bers than previously possible). Regular members of the
Society who are corresponding authors of articles pub-
lished in the Journal will continue to receive one free color
figure as a benefit of membership. The rigorous quality
peer review and editorial process will remain the same for
authors submitting to and publishing in the Journal. We
will continue to support full compliance with the en-
hanced public access requirements of the National Insti-
tutes of Health, Wellcome Trust, and other funding bodies
by depositing final published articles on behalf of such
authors in PubMed Central (PMC) and UKPMC for public
release.
You will notice a new look and a richer experience
when you visit the Journal online. As Open Access poli-
cies and other scientific publishing practices evolve, we
will be able to meet them effectively and always with an
eye to maintaining the Society mission. All visitors to the
Journal site will be able to preview CME test questions.
Journal content will be housed not only on the main jour-nal platform but will also be reachable through extended
platforms such as ScienceDirect and JournalsConsult.
Our commitment and expertise does not fade with a
move to managed publishing. We consider this the next
phase in our stewardship of the Journal, serving as ad-
vocates of the science as well as our constituents – the
readers, authors, and Society members who comprise
our scientific community. We remain as engaged as ever
in the success of the Journal in fulfilling the scientific
mission of the Society. Our goal in moving to managed
publication is preservation and broadening of the same
tenets that have made The American Journal of Pathology
successful under self-publication, and we welcome
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